When the Food and Drug Administration approved a new pancreatic cancer drug called Rasonque last month, researchers and patient advocates celebrated. According to patients and clinicians interviewed by STAT, the regulatory green light immediately triggered the closure of the manufacturer’s expanded access program, leaving families caught in a dangerous transition period while commercial insurance coverage … Read more
Johnson & Johnson shares finished at a record close above $275, extending their winning streak to seven straight sessions, according to market data. UBS analysts raised their price target on the healthcare giant to $320 per share from $280, pointing to an inflecting top-line growth rate and a shift toward higher-margin products. Jim agreed with … Read more
A new Phase Ib clinical trial will evaluate whether a once-weekly dry powder nasal spray called INNA-051 can prime innate immune defenses and prevent viral complications in adult asthma patients, according to developer ENA Respiratory. The trial is backed by AUD $2.98 million in funding awarded through Biointelect Venturer, utilizing support from the Australian Government’s … Read more
New treatments for pattern hair loss are driving a surge in biotech stock valuations as Wall Street targets the condition as an untapped consumer market. How New Hair Loss Drug Stocks Are Surging The promise of novel treatments has driven substantial market gains for pharmaceutical developers. Meanwhile, Absci stock has more than doubled throughout the … Read more
Retatrutide Black Market Lawsuits Target Six Compounding Pharmacies and Online Sellers Pharmaceutical analysts note that demand for weight-loss treatments has fueled a thriving online market for products claiming to contain weight-loss drugs. Illicit sellers frequently attempt to bypass federal oversight by labeling products as “research-use only.” Testing of seized black-market inventory reveals severe safety hazards, … Read more
Eli Lilly Expands Early Access to Retatrutide Following Patient Advocacy Eli Lilly has confirmed it will allow a broader range of patients to apply for early access to its unapproved obesity drug, retatrutide. The decision follows a report by STAT regarding a 79-year-old patient who previously received special access to the medication. The pharmaceutical company … Read more
Scientists are studying how chronic inflammation triggered by diseased gums and bacteria may contribute to systemic conditions including heart disease, diabetes, and cognitive decline, according to recent research. The emerging science connects oral health to whole-body wellness, challenging the traditional divide between medicine and dentistry. The Mouth-Body Connection: How Gum Disease Drives Systemic Inflammation Researchers … Read more
Researchers at the University of California San Diego and the Rady Children’s Institute for Genomic Medicine have successfully treated two children with SCN2A-related developmental epileptic encephalopathy (DEE) using personalized, allele-selective antisense oligonucleotides (ASOs). According to a study published July 21, 2026, in Nature Medicine, the therapy reduced seizure frequency by up to 90%, improved developmental … Read more
Eli Lilly and Company is acquiring biotech firm AtaiBeckley for an up-front payment of $2.8 billion to integrate the psychedelic drug candidate BPL-003 into its neuroscience portfolio. According to company terms, Lilly will pay $6.75 per outstanding share, with potential milestone payments reaching an additional $1 billion ($2.50 per share), according to the deal terms. … Read more
Johnson & Johnson (JNJ) shares are navigating a period of volatility as investors weigh the company’s pharmaceutical growth against broader market rotations and macroeconomic pressures. According to FactSet, the healthcare giant faces a critical test during its second-quarter earnings report, with analysts closely monitoring the performance of key oncology and immunology drugs to justify the … Read more